Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy IntroductionBiotherapy for neuroendocrine tumors essentially includes treatment with somatostatin analogues and α interferons (IFNs) [1,2,3,4,5,6,7,8,9]. A large number of tyrosine kinase, angiogenesis as well as mTOR inhibitors have recently been developed and also attempted in the treatment of neuroendocrine tumors, but these new agents will not be covered by these guidelines due to lack of data.Somatostatin AnaloguesThese agents should be used according to earlier published guidelines. The main indication for the use of somatostatin analogues is treatment of functioning neuroendocrine tumors causing hormone-related clinical syndromes. Somatostatin analogues might block the release of various active agents that cause the clinical syndrome and thereby reduce the symptoms and improve quality of life. The drug has been discussed also for use in non-functioning neuroendocrine tumors, but available data are still contradictory and controversial. Randomized trials are ongoing.What Is Necessary in Preparation for Somatostatin Analogue Treatment?Basal investigations before biotherapy with somatostatin analogues include electrocardiogram (ECG) and ultrasound of the gallbladder. With regard to the biochemistry, blood cell count transaminases, bilirubin, blood glucose, electrolytes including Ca, P, creatinine and vitamin B12 should be analyzed. Besides that, blood pressure and body weight, TSH and ft4 should also be included in the standard evaluation. For evaluation http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neuroendocrinology Karger

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy

Download PDF
5 pages

Loading next page...
 
/lp/karger/enets-consensus-guidelines-for-the-standards-of-care-in-neuroendocrine-AwoNijS3YV

References (10)

Publisher
Karger
Copyright
© 2008 S. Karger AG, Basel
ISSN
0028-3835
eISSN
1423-0194
DOI
10.1159/000183751
Publisher site
See Article on Publisher Site

Abstract

IntroductionBiotherapy for neuroendocrine tumors essentially includes treatment with somatostatin analogues and α interferons (IFNs) [1,2,3,4,5,6,7,8,9]. A large number of tyrosine kinase, angiogenesis as well as mTOR inhibitors have recently been developed and also attempted in the treatment of neuroendocrine tumors, but these new agents will not be covered by these guidelines due to lack of data.Somatostatin AnaloguesThese agents should be used according to earlier published guidelines. The main indication for the use of somatostatin analogues is treatment of functioning neuroendocrine tumors causing hormone-related clinical syndromes. Somatostatin analogues might block the release of various active agents that cause the clinical syndrome and thereby reduce the symptoms and improve quality of life. The drug has been discussed also for use in non-functioning neuroendocrine tumors, but available data are still contradictory and controversial. Randomized trials are ongoing.What Is Necessary in Preparation for Somatostatin Analogue Treatment?Basal investigations before biotherapy with somatostatin analogues include electrocardiogram (ECG) and ultrasound of the gallbladder. With regard to the biochemistry, blood cell count transaminases, bilirubin, blood glucose, electrolytes including Ca, P, creatinine and vitamin B12 should be analyzed. Besides that, blood pressure and body weight, TSH and ft4 should also be included in the standard evaluation. For evaluation

Journal

Neuroendocrinology – Karger

Published: Jan 1, 2008

There are no references for this article.